comparemela.com

Latest Breaking News On - Pacira biosciences company profile - Page 7 : comparemela.com

Pacira BioSciences, Inc (NASDAQ:PCRX) Receives $62 73 Consensus Target Price from Analysts

Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Rating) has earned a consensus rating of “Moderate Buy” from the thirteen analysts that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price target […]

46,800 Shares in Pacira BioSciences, Inc (NASDAQ:PCRX) Purchased by Hussman Strategic Advisors Inc

Hussman Strategic Advisors Inc. bought a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Rating) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 46,800 shares of the company’s stock, valued at approximately $1,807,000. Hussman Strategic Advisors Inc. owned […]

Pacira BioSciences (NASDAQ:PCRX) Price Target Lowered to $62 00 at Piper Sandler

Pacira BioSciences (NASDAQ:PCRX – Get Rating) had its target price reduced by Piper Sandler from $63.00 to $62.00 in a research report sent to investors on Tuesday morning, The Fly reports. Other equities research analysts have also issued reports about the company. StockNews.com started coverage on Pacira BioSciences in a research report on Thursday, March […]

Pacira BioSciences (NASDAQ:PCRX) Stock Rating Reaffirmed by Needham & Company LLC

Pacira BioSciences (NASDAQ:PCRX – Get Rating)‘s stock had its “buy” rating reissued by Needham & Company LLC in a report issued on Thursday, Benzinga reports. They currently have a $60.00 price target on the stock. Needham & Company LLC’s price target would suggest a potential upside of 29.00% from the company’s previous close. PCRX has […]

Brokerages Set Pacira BioSciences, Inc (NASDAQ:PCRX) Target Price at $64 36

Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Rating) has been given a consensus rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month target […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.